EUVIMEDEUVIMED entdecken
Crossref

EE160 AN ECONOMIC MODEL TO ESTIMATE THE 1-YEAR COSTS AND OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) TREATED WITH ENZALUTAMIDE PLUS RADIUM-223 (RA-223) OR LUTETIUM-177 VIPIVOTIDE TETRAXETAN (177LU-PSMA-617)

Sreevalsa Appukkuttan, Bashir Kalayeh, Jean Lee, William Ngantung, Matia Saeedian

Value in Health · 2026-06 · 29 (6) · S93

DOI: 10.1016/j.jval.2026.03.455 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Sreevalsa Appukkuttan und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Appukkuttan, S., Kalayeh, B., Lee, J., Ngantung, W., & Saeedian, M. (2026). EE160 AN ECONOMIC MODEL TO ESTIMATE THE 1-YEAR COSTS AND OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) TREATED WITH ENZALUTAMIDE PLUS RADIUM-223 (RA-223) OR LUTETIUM-177 VIPIVOTIDE TETRAXETAN (177LU-PSMA-617). Value in Health, 29(6), S93. https://doi.org/10.1016/j.jval.2026.03.455

Vancouver

Appukkuttan S, Kalayeh B, Lee J, Ngantung W, Saeedian M. EE160 AN ECONOMIC MODEL TO ESTIMATE THE 1-YEAR COSTS AND OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) TREATED WITH ENZALUTAMIDE PLUS RADIUM-223 (RA-223) OR LUTETIUM-177 VIPIVOTIDE TETRAXETAN (177LU-PSMA-617). Value in Health. 2026;29(6):S93. doi:10.1016/j.jval.2026.03.455

BibTeX
@article{Appukkuttan2026,
  author = {Appukkuttan, Sreevalsa and Kalayeh, Bashir and Lee, Jean and Ngantung, William and Saeedian, Matia},
  title = {EE160 AN ECONOMIC MODEL TO ESTIMATE THE 1-YEAR COSTS AND OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) TREATED WITH ENZALUTAMIDE PLUS RADIUM-223 (RA-223) OR LUTETIUM-177 VIPIVOTIDE TETRAXETAN (177LU-PSMA-617)},
  journal = {Value in Health},
  year = {2026},
  volume = {29},
  number = {6},
  pages = {S93},
  doi = {10.1016/j.jval.2026.03.455}
}
Kostenlos starten →